Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Steenokkerzeel – page 64

1 955 clinical trials in Steenokkerzeel, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steenokkerzeel at a glance
1 955
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 955 trials in Steenokkerzeel

Open in trial search

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Colorectal cancer

Not yet recruiting

A phase 1/2 study evaluating safety, pharmacokinetics and efficacy of SOT109 in patients with advanced unresectable or metastatic colorectal cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:SOTIO Biotech a.s.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Safety and Immune Response of GBS-NN/NN2 and Tdap Vaccines in Preventing Group B Strep Infection in Healthy Women Aged 18-49

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GBS-NN
  • Sponsor:Minervax ApS

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Thrombosis prophylaxis

Not yet recruiting

Randomized trial of standard vs high-dose enoxaparin and sodium chloride for preventing clots in critically ill ICU patients at high risk of thrombosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Hopital Erasme

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Psoriasis+1

Not yet recruiting

Diagnostic PET/CT Study with [AL[18F]F]FAPI-74 in Psoriasis Patients with Arthralgia for Early Detection of Psoriatic Arthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Steenokkerzeel

What the registry says about research in the country

01 Multiple Sclerosis Research

Innovative clinical trials focusing on relapsing multiple sclerosis, evaluating the effectiveness of new therapeutic compounds compared to established treatments.

  • Treatment Comparison Studies
  • Relapse Reduction Research
  • Safety Assessment Protocols

These studies aim to advance treatment options for patients experiencing MS relapses.

02 Progressive MS Studies

Specialized research examining nonrelapsing secondary progressive multiple sclerosis, with emphasis on disability progression prevention.

  • Disease Progression Analysis
  • Novel Therapeutic Approaches
  • Long-term Disability Management

Current trials are exploring innovative treatments to slow disease advancement.

03 Remyelination Research

Groundbreaking studies investigating brain remyelination and neurodegeneration in progressive multiple sclerosis using established medications in new applications.

  • Walking Speed Assessment
  • Disease Progression Markers
  • Alternative Treatment Applications

Research focuses on long-term treatment outcomes over 96-week periods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.